NVS vs. COR
NVS (Novartis AG) and COR (Cencora Inc.) are both stocks. Both are in the Healthcare sector — NVS in Drug Manufacturers - General, COR in Medical Distribution. Over the past 10 years, NVS returned 11.14%/yr vs 17.47%/yr for COR. At a 0.27 correlation, their price movements are largely independent.
Performance
NVS vs. COR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVS achieves a 14.40% return, which is significantly higher than COR's -16.27% return. Over the past 10 years, NVS has underperformed COR with an annualized return of 11.14%, while COR has yielded a comparatively higher 17.47% annualized return.
NVS
- 1D
- -0.55%
- 1M
- 2.22%
- YTD
- 14.40%
- 6M
- 18.98%
- 1Y
- 30.60%
- 3Y*
- 19.57%
- 5Y*
- 14.77%
- 10Y*
- 11.14%
COR
- 1D
- 0.07%
- 1M
- 10.42%
- YTD
- -16.27%
- 6M
- -18.27%
- 1Y
- -3.81%
- 3Y*
- 17.14%
- 5Y*
- 20.65%
- 10Y*
- 17.47%
NVS vs. COR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NVS Novartis AG | 14.40% | 46.95% | 0.02% | 16.14% | 8.06% | -3.65% | 3.34% | 13.92% | 5.95% | 19.42% |
COR Cencora Inc. | -16.27% | 51.48% | 10.37% | 25.33% | 26.26% | 44.09% | 23.37% | 23.51% | -17.57% | 19.51% |
Correlation
The correlation between NVS and COR is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.28 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.35 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.34 |
Correlation (All Time) Calculated using the full available price history since Nov 7, 1996 | 0.27 |
Fundamentals
NVS:
$293.28B
COR:
$55.03B
NVS:
$6.99
COR:
$13.07
NVS:
21.90
COR:
21.55
NVS:
1.48
COR:
10.24
NVS:
5.29
COR:
0.17
NVS:
7.62
COR:
16.20
NVS:
$56.05B
COR:
$328.68B
NVS:
$42.19B
COR:
$11.66B
NVS:
$22.40B
COR:
$3.64B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVS vs. COR — Risk / Return Rank
NVS
COR
NVS vs. COR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novartis AG (NVS) and Cencora Inc. (COR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVS | COR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.60 | ||
| Sortino ratioReturn per unit of downside risk | +2.06 | ||
| Omega ratioGain probability vs. loss probability | 1.26 | 1.01 | +0.25 |
| Calmar ratioReturn relative to maximum drawdown | 2.43 | -0.12 | +2.55 |
| Martin ratioReturn relative to average drawdown | 5.88 | -0.33 | +6.21 |
Loading charts...
Drawdowns
NVS vs. COR - Drawdown Comparison
The maximum NVS drawdown since its inception was -42.10%, smaller than the maximum COR drawdown of -71.01%. Use the drawdown chart below to compare losses from any high point for NVS and COR.
Loading charts...
Drawdown Indicators
| NVS | COR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -42.10% | -71.01% | +28.91% |
Max Drawdown (1Y)Largest decline over 1 year | -12.65% | -32.44% | +19.79% |
Max Drawdown (3Y)Largest decline over 3 years | -19.95% | -32.44% | +12.49% |
Max Drawdown (5Y)Largest decline over 5 years | -20.42% | -32.44% | +12.02% |
Max Drawdown (10Y)Largest decline over 10 years | -26.03% | -32.44% | +6.41% |
Current DrawdownCurrent decline from peak | -6.46% | -24.54% | +18.08% |
Average DrawdownAverage peak-to-trough decline | -10.92% | -13.62% | +2.70% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.23% | 11.68% | -6.45% |
Volatility
NVS vs. COR - Volatility Comparison
Novartis AG (NVS) has a higher volatility of 7.18% compared to Cencora Inc. (COR) at 6.51%. This indicates that NVS's price experiences larger fluctuations and is considered to be riskier than COR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVS | COR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.18% | 6.51% | +0.67% |
Volatility (6M)Calculated over the trailing 6-month period | 14.96% | 26.93% | -11.97% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.02% | 30.20% | -9.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 18.89% | 22.30% | -3.41% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 19.64% | 27.48% | -7.84% |
Dividends
NVS vs. COR - Dividend Comparison
NVS's dividend yield for the trailing twelve months is around 3.12%, more than COR's 0.83% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
COR Cencora Inc. | 0.83% | 0.67% | 0.93% | 0.96% | 1.13% | 5.13% | 6.74% | 7.48% | 2.07% | 1.61% | 1.77% | 1.17% |
NVS Novartis AG | 3.12% | 2.90% | 3.84% | 3.44% | 3.70% | 3.86% | 3.22% | 3.03% | 3.47% | 3.24% | 3.73% | 3.10% |
Financials
NVS vs. COR - Financials Comparison
This section allows you to compare key financial metrics between Novartis AG and Cencora Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVS vs. COR - Profitability Comparison
NVS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a gross profit of 10.07B and revenue of 13.52B. Therefore, the gross margin over that period was 74.4%.
COR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cencora Inc. reported a gross profit of 3.59B and revenue of 78.36B. Therefore, the gross margin over that period was 4.6%.
NVS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported an operating income of 4.24B and revenue of 13.52B, resulting in an operating margin of 31.3%.
COR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cencora Inc. reported an operating income of 1.14B and revenue of 78.36B, resulting in an operating margin of 1.5%.
NVS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novartis AG reported a net income of 3.16B and revenue of 13.52B, resulting in a net margin of 23.3%.
COR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cencora Inc. reported a net income of 1.64B and revenue of 78.36B, resulting in a net margin of 2.1%.
Frequently Asked Questions
NVS and COR have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVS has higher volatility (7.18%) compared to COR (6.51%). In terms of maximum drawdown, NVS dropped -42.10% vs COR's -71.01%.
NVS currently has the higher Sharpe Ratio (1.47 vs -0.13), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVS and COR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer